Protalix shares boosted by Fabrazyme comparison

5 April 2022

Israeli pharma company Protalix BioTherapeutics (NYSE American: PLX) and family-owned Italian drugmaker Chiesi have announced positive top-line results from the 24-Month Phase III BALANCE trial of PRX-102 (pegunigalsidase alfa) in Fabry disease.

PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study versus agalsidase beta, a drug marketed by Sanofi (Euronext: SAN) as Fabrazyme.

Monday’s announcement sent shares in Protalix up by 42% by the close.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK